ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 791

Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

May Choi1, Emily Mirizio 2, Fernanda Quinteros 3, Katherine Buhler 4, Marvin Fritzler 1 and Kathryn Torok 5, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Pittsburgh, Pittsburgh, 3University of Calgary, Calgary, 4University of Calgary, Calgary, Canada, 5UPMC Children's Hospital of Pittsburgh, Pittsburgh

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ANA, autoantibodies, Juvenile scleroderma, systemic sclerosis and localized scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We previously demonstrated that the presence of certain autoantibodies (Aab) is associated with deep tissue and internal organ involvement compared to pediatric healthy controls. In this study, a wider screening Aab array was used in a study to compare pediatric LS to pediatric systemic sclerosis (SSc).

Methods: A total of 133 pediatric patients (n=109 LS and 24 SSc) were included. Sera was tested for antinuclear antibodies (ANA) using indirect immunofluorescence (IIF) on HEp-2 cells (Inova Diagnostics, San Diego, CA) where a titre of equal to or greater than 1/80 was considered to be positive. Circular heat maps were generated to compare the frequency of ANA patterns in each group. The international consensus on ANA patterns (ICAP, www.anapatterns.org) nomenclature was used to denote ANA IIF pattern nomenclature.

Results: A total of 59/109 (54%) LS patients and 16/24 (67%) SSc patients were ANA positive. LS had the greatest number of distinct ANA patterns (n=11) compared to SSc (n=7) (Figure 1). AC-4 (nuclear speckled) was the most common pattern (23/109, 21%) while AC-8/9/10 (nucleolar) was the least common in LS (2/109, 2%). The opposite was true for SSc where AC-8/9/10 (9/24, 38%) was the most common and AC-4 was uncommon (3/24, 13%). Other ANA IIF patterns such as AC-2 (dense fine speckles) (4/109, 4%) and AC-24 (centrosome) (8/109, 7%) were seen in LS, but was absent or rare in SSc.

Conclusion: Pediatric SSc had higher frequency of ANA positivity compared to pediatric LS, as clinically expected, but not by a high margin. Interestingly, patients with LS had more heterogeneous expression of ANA patterns, including patterns that are rarely seen in SSc such as AC-24 (centrosome). Furthermore, since the centrosome is in the cytoplasm, the centrosome pattern would not be reported by laboratories that only report nuclear IIF patterns as a positive ANA. Therefore, an ANA test that includes nuclear, cytoplasmic, and mitotic patterns should be considered as the screening test in patients with scleroderma, especially LS.

Figure 1. Circular heat maps for anti-nuclear antibody indirect immunofluorescence patterns in localized scleroderma -A- and systemic sclerosis -B- pediatric patients using the international consensus on ANA patterns -ICAP- nomenclature -www.anapatterns.org-.


Disclosure: M. Choi, None; E. Mirizio, None; F. Quinteros, None; K. Buhler, None; M. Fritzler, Alexion Canada, 7, BioRad, 5, Dr. Fooke Laboratorien GmbH, 5, Euroimmun GmbH, 5, 7, ImmunoConcepts, 7, Inova Diagnostics, 5, 7, 8, Inova Diagnostics Inc. San diego, CA, 5, Inova Dx, Mikrogen GmbH, 5, Werfen International, 5; K. Torok, None.

To cite this abstract in AMA style:

Choi M, Mirizio E, Quinteros F, Buhler K, Fritzler M, Torok K. Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/closing-the-seronegative-gap-in-pediatric-localized-scleroderma-and-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/closing-the-seronegative-gap-in-pediatric-localized-scleroderma-and-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology